Ready... it's all in how you look or approach things.
If you'd sold at $12 and bought back in at $9... yes, you'd be happy. I'd be happy, had I done the same thing.
But, this is what you or I could have done with the knowledge we have now. At the time, had you sold at $12, and waited for it to fall to $9... and instead, whatever the company is being so quiet for came sooner, and the stock flew to $20, I'm pretty sure you'd be kicking yourself even harder.
So you can look at what's happened thus far and be dissatisfied with yourself, or those of us who are long whom perhaps you feel persuaded you into not selling, or you can adjust. So far, I'm assuming all your gains or losses are on paper. Nothing's real until you sell anyway.
And so, tomorrow, or Friday, or Monday, or next week, if a PR comes out with particularly good news, you won't mind that you didn't sell at $12. That decision you made not to sell will be in the past and you will once again be in happy land.
As to those milestones and catalysts that Linda spoke of that they've not met...
She said they would update us on the data for the 55 information arm.
They have.
She said they would give us up-to-date data on the P1 Direct patients.
They have.
She said they would tell us the indications they would be focusing on for their P2 trials for Direct.
They have.
Why else but for the milestones and catalysts they've reached so far do you think the stock price has risen as high as the mid $12s?
Still up for this year...
1st IA on L
HE in Germany
PEI 2nd step in the UK
Initiate the P2 trials for Direct
Partnership for Checkpoint Inhibitor